British drugs firm GSK settles US drug disputes for $3.0 bln
November 3, 2011 in Medications
GlaxoSmithKline said on Thursday it had agreed to pay $3.0 billion (2.2 billion euros) to settle long-running disputes with the US government over how the British pharmaceuticals group marketed and developed drugs.
GlaxoSmithKline said in a statement that it had "reached an agreement in principle with the US government to conclude the company's most significant ongoing Federal government investigations."
The investigations included the probing of GSK's sales and marketing practices, begun by the US Attorney's office of Colorado in 2004 and later taken over by the US Attorney's Office of Massachusetts.
And they also referred to the Department of Justice's probe into the development and marketing of its former blockbuster diabetes drug Avandia.
GSK said that it had already set aside sufficient cash funds to pay the legal costs, although some terms still needed to be agreed.
GSK chief executive Andrew Witty said the $3.0 billion deal was "a significant step toward resolving difficult, long-standing matters which do not reflect the company that we are today."
He added in a statement: "In recent years, we have fundamentally changed our procedures for compliance, marketing and selling in the US to ensure that we operate with high standards of integrity and that we conduct our business openly and transparently."
(c) 2011 AFP
-
GlaxoSmithKline reports return to profit in second quarter
Jul 26, 2011 |
not rated yet |
0
-
Drugs firm GSK eyes India acquisitions: chief executive
Oct 03, 2011 |
not rated yet |
0
-
GSK to take $3.4 bln Avandia legal charge
Jan 17, 2011 |
not rated yet |
0
-
GlaxoSmithKline posts rising Q3 profits
Oct 26, 2011 |
not rated yet |
0
-
Glaxo pays 41 million to settle US drug quality matter
Jun 23, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
-
Marie Curie's leukemia
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
Acne pill benefits outweigh blood clot risk: EU agency
Europe's medicines watchdog said Friday the benefits of acne drug Diane-35, also widely used as a contraceptive, outweigh the risk of developing blood clots in the veins—when correctly prescribed.
Medications
May 17, 2013 |
not rated yet |
0
First influenza vaccine brought to clinical testing
Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their ...
Medications
May 17, 2013 |
5 / 5 (1) |
0
Aspirin not always best treatment for many individuals
(Medical Xpress)—An aspirin a day may not always keep heart disease away, say two University of Florida cardiologists. But a new algorithm they have developed outlines factors physicians should weigh as ...
Medications
May 16, 2013 |
3.5 / 5 (2) |
0
|
FDA: lower ambien's dose to prevent drowsy driving
(HealthDay)—The U.S. Food and Drug Administration has approved new, lower-dose labeling for the popular sleep drug Ambien (zolpidem) in an effort to cut down on daytime drowsiness that could be a hazard ...
Medications
May 15, 2013 |
not rated yet |
0
Simponi approved for ulcerative colitis
(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.
Medications
May 15, 2013 |
not rated yet |
0
Ketamine shows significant therapeutic benefit in people with treatment-resistant depression
Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the ...
Consuming coffee linked to lower risk of detrimental liver disease, study finds
Regular consumption of coffee is associated with a reduced risk of primary sclerosing cholangitis (PSC), an autoimmune liver disease, Mayo Clinic research shows. The findings were being presented at the Digestive Disease ...
Research examines new methods for managing digestive health
Research presented at Digestive Disease Week (DDW) explores new methods for managing digestive health through diet and lifestyle.
New smartphone application improves colonoscopy preparation
The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...
New research identifies risks, interventions for children's GI health
An increasing number of U.S. children are experiencing gastrointestinal issues that require interventions to resolve, according to research presented at Digestive Disease Week (DDW).
New research identifies practice changes to improve value and quality of GI procedures
There are significant cost and risk factors associated with two procedures commonly used to diagnose or treat gastrointestinal problems, according to research presented at Digestive Disease Week (DDW).
